Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.

[1]  N. Thatcher,et al.  O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. , 1991, Cancer research.

[2]  M. Namer,et al.  Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.

[3]  D. Waxman,et al.  Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review. , 1990, Cancer research.

[4]  P. Vassalli,et al.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis , 1989, The Journal of experimental medicine.

[5]  P. Kleihues,et al.  Inhibition of the hepatic O6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. , 1989, Biochemical pharmacology.

[6]  M. D’Incalci,et al.  Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. , 1988, Cancer treatment reviews.

[7]  S. Gerson,et al.  Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase. , 1988, Cancer research.

[8]  C. Jacquillat,et al.  Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. , 1987, Cancer research.

[9]  R. Janzer,et al.  In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). , 1986, Biochemical pharmacology.

[10]  M. Dolan,et al.  Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. , 1986, Cancer research.

[11]  P. Houghton,et al.  O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Dolan,et al.  Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N'-nitro-N-nitrosoguanidine. , 1984, Carcinogenesis.

[13]  M. Boyd,et al.  Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity. , 1984, The Journal of pharmacology and experimental therapeutics.

[14]  D. Scudiero,et al.  Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. , 1984, Cancer research.

[15]  T. Lindahl,et al.  Suicide inactivation of the E. coli O6‐methylguanine‐DNA methyltransferase. , 1982, The EMBO journal.

[16]  M. D’Incalci,et al.  O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. , 1991, Anticancer research.

[17]  P. van Bladeren,et al.  Glutathione S-transferases in relation to their role in the biotransformation of xenobiotics. , 1990, Chemico-biological interactions.

[18]  P. Kleihues,et al.  O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. , 1984, Carcinogenesis.

[19]  L. Erickson,et al.  Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. , 1983, Carcinogenesis.